TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Dietary Treatment for Chronic Urticaria

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Urticaria +/- angioedema present for a minimum of 6 weeks;~* Agree to be on anti-histamine prn;~* Age older than 8 years old, with no upper age limit;~* Causes such as parasite infestation, microbial and viral infections, autoimmune disease, or other pathology that could account for the U/A/P should be excluded;~* Skin prick test and/or radioallergosorbent (RAST) test are negative for all food allergens tested, or patient had achieved no symptomatic improvement after strict avoidance of all skin test-positive foods;~Exclusion Criteria:~* Pregnant or breast feeding women;~* Patients who is taking central nervous system (CNS) acting agents (including tranquilizers, antidepressants, sedatives, hypnotics or antiepileptics) at any time;

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Treatment group (on low histamine diet) (Type: EXPERIMENTAL): 78 subjects who come to Allergy Centre for treatment of idiopathic urticaria, with or without angioedema and pruritus (U/A/P), will be randomized into two parallel groups; treatment group (TG) will be asked to follow a histamine-restricted diet for 4 weeks and the control group (CG) will be asked to follow a well-balanced diet instructed by a dietitian for 4 weeks. A well-balanced diet for the CG subject is tailor-made by the dietitian according to subject's usual intake to ensure that the subject's energy requirement is met and all food groups are consumed.
- Well-balanced diet (Type: ACTIVE_COMPARATOR): Diet tailor-made by the dietitian according to subject's usual intake to ensure that the subject's energy requirement is met and all food groups are consumed.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Ceftriaxone in the Management of Bipolar Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* DSM-IV diagnosis of bipolar disorder~* Presence of a current major depressive episode on the SCID~* Score of 17 or greater on the HDRS~* Failure to respond to two previous medication trials~* Capable of giving voluntary written consent~Exclusion Criteria:~* Hypersensitivity to penicillin or cephalosporin, resulting in anaphylaxis~* Significant current substance dependence/abuse within 3 months preceding the trial~* Significant history of intravenous drug abuse~* Active suicidal ideation~* Pregnant/lactating mothers~* Significant medical history~* Patients on anticoagulation treatment~* Patients who test positive for HIV or Hep B or C

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: ACTIVE_COMPARATOR): None
- P (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Magnesium as an Adjunct for Pain Treatment After Surgery for Thumb Base Arthrosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Planned for surgery of thumb base arthrosis with trapeziectomy with ligament reconstruction tendon interposition.~* Age 18 years or older.~* low anesthetic risk, ASA class 1 or 2.~* Be able to take oral medication.~* Be able to read and communicate in Swedish.~Exclusion Criteria:~* Age under 18 years.~* Heartfailure, kidney failure, ischemic hearth disease.~* Previous neuropathic pain or complex pain syndrome.~* Serious psychiatric morbidity~* Not able to communicate in Swedish~* Skin problems that makes the application of NoL-sensor impossible.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Magnesium (Type: ACTIVE_COMPARATOR): Given 1000 mg oral magnesiumcitrate once daily (4\*250mg) during the day of surgery and the next 6 Days.
- Placebo (Type: PLACEBO_COMPARATOR): Given placebo once daily during the day of surgery and the next 6 Days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Study of Etanercept in Subjects With Rheumatoid Arthritis Who Have Had an Inadequate Response to Adalimumab or Infliximab Plus Methotrexate

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Met the 1987 ACR Revised Criteria for RA~2. A history of inadequate response to infliximab or adalimumab in combination with methotrexate.~3. A stable dose of oral methotrexate for at least 6 weeks before the baseline visit.~Exclusion Criteria:~1. ACR functional class IV~2. Prior treatment with etanercept; both infliximab and adalimumab; or any immunosuppressive biologic agent other than infliximab or adalimumab.~3. Discontinuation of infliximab or adalimumab for a primary reason other than inadequate efficacy response.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- Group A (Type: EXPERIMENTAL): Subjects who are mAb ADA positive
- Group B (Type: EXPERIMENTAL): Subjects who are mAb ADA negative
- Group C (Type: PLACEBO_COMPARATOR): Subjects who are mAb ADA positive
- Group D (Type: PLACEBO_COMPARATOR): Subjects who are mAb ADA negative

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Trial of GS-9219 in Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Relapsed or refractory CLL, NHL or MM~* ECOG Performance Status of 0, 1, or 2~* Adequate organ function (protocol defined)~* ECG without evidence of clinically significant ventricular arrhythmias~Exclusion Criteria:~* AIDS-related lymphoma~* Subjects with NHL who present exclusively with non-measurable lesions~* Subjects with MM who have non-secretory and/or non-measurable disease~* Recent anticancer therapy (chemotherapy, radiotherapy, and/or biotherapy)within four weeks prior to starting treatment~* Evidence of pulmonary fibrosis~* Other concurrent malignancy~* Uncontrolled concurrent illness~* Receiving chronic, systemically administered steroids~* Known hypersensitivity to nucleoside analogues

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GS-9219 (Type: EXPERIMENTAL): Escalating doses of GS-9219 (5, 8, 11.5, 16, 22.5, 31.5, 44, and 61.5 mg/m\^2) until determination of the maximum tolerated dose (MTD)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Compare Efficacy and Safety of Raltitrexed-based and 5fu-based Neoadjuvant Chemotherapy for Colorectal Liver Metastasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologically confirmed chinese colorectal cancer patients and imaging detection confirmed liver metastasis~2. previously no treatment for liver metastasis or Primary tumor had been removed and last additional chemotherapy over one year~3. Age of≥18 and ≤75~4. Adequate organ functions, as determined by normal bone marrow function (absolute neutrophil count2 x 109/L, platelets 100 x 109/L, White blood cells 4 x 109/L), liver function (serum bilirubin ≤ 2.5 x ULN, serum transaminases ≤2. 5x ULN)~5. ECOG≤1~6. Life Expectancy\>6months~7. Signed written informed consent~8. Expected adequacy of follow-up~Exclusion Criteria:~1. Lesion is too small to assess by imaging~2. Extrahepatic metastases~3. Any anticancer chemotherapy in development within 4 weeks prior to study entry~4. Concurrent uncontrolled illness such as infection~5. Be allergic to medicines in the study~6. Pregnant or nursing patients~7. Fertile women (\< 2 years after last menstruation) and men of childbearing potential not willing to use effective means of contraception.~8. Not willing or incapable to comply with all study visits and assessments~9. Evidence of any other disease, metabolic dysfunction, physical examination finding or laboratory finding giving reasonable suspicion of a disease or condition that puts the patient at high risk for treatment-related complications.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Raltitrexed-based chemotherapy (Type: EXPERIMENTAL): Raltitrexed plus Oxaliplatin/Raltitrexed plus Irinotecan
- 5-fluorouracil-based chemotherapy (Type: ACTIVE_COMPARATOR): 5-fluorouracil plus Oxaliplatin/5-fluorouracil plus Irinotecan

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Double-Blind Placebo-Controlled CIN Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Inpatients scheduled for CT scan of abdomen and/or pelvis~* Had surgery in the last 4 weeks~* Stable renal function (based on serum creatinine-last two lab values +/- 0.3 of each other, with most recent within 5 days of CT)~* Suspected infection or fluid collection in abdomen and/or pelvis~Exclusion Criteria:~* Pregnant~* Severe Allergy (anaphylaxis) to contrast~* Dialysis in last 7 days~* Received intravascular iodinated contrast in last 48 hours~* CT of abdomen and pelvis in last 7 days shows no fluid collection~* Prisoners~* CT ordered for an indication that requires (eg, CT angiogram) or contraindicates (eg, renal stone CT) the administration of intravascular contrast

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Iopamidol 300 (Contrast) (Type: ACTIVE_COMPARATOR): Subjects scheduled for a clinical CT will be randomized to receive weight-based low-osmolality iodinated contrast with the CT. All subjects will receive a minimum of 1 mL/kg/hr of isotonic volume expansion for at least three hours before and three hours after the CT.
- Placebo (Normal Saline) (Type: PLACEBO_COMPARATOR): Subjects scheduled for a standard of care CT will be randomized to receive weight-based normal saline instead of contrast material with the CT. All subjects will receive a minimum of 1 mL/kg/hr of isotonic volume expansion for at least three hours before and three hours after the CT.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Phase 2 Dasatinib Combo With Smoothened (SMO) Antagonist (BMS-833923)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects ≥ 18 years of age who have signed informed consent~* Philadelphia positive Chronic Myeloid Leukemia (CML) in chronic phase~* Previously untreated chronic phase CML, except for Anagrelide or Hydroxyurea.~* Eastern Co-Operative Group (ECOG) Performance Status (PS) Score 0 - 2~Exclusion Criteria:~* Known Abl-kinase T315I or T315A mutation~* Serious or uncontrolled medical disorder (including infection or cardiovascular disease) or dementia or other serious psychiatric condition~* Prior chemotherapy.~* Women who are pregnant or breastfeeding or Women of Child Bearing Potential (WOCBP) who are unwilling or unable to use an acceptable method to avoid pregnancy during the entire study period.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1: Dasatinib (Type: ACTIVE_COMPARATOR): None
- Arm2: Dasatinib + BMS-833923 (Type: EXPERIMENTAL): Dasatinib for 1 year followed by dasatinib plus BMS-833923 for 2 years followed by dasatinib alone for approximately 2 years; depending on response

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Examine the Safety and Efficacy of Drospirenone and Ethinyl Estradiol (YAZ) Versus Placebo In HS

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
INCLUSION CRITERIA~1. Female Subjects 14-45 years of age who have achieved spontaneous menarche.~2. Clinical diagnosis of hidradenitis suppurativa of stage II or greater on the Hurley scale.~3. Willing and able to understand and sign informed consent.~4. Able to complete study and comply with study procedures.~EXCLUSION CRITERIA~1. Change is use of oral or topical antibiotics in past 90 days.~2. Use of intralesional steroids within 30 days.~3. Use of isotretinoin in past six months.~4. Use of biologics such as Infliximab (Remicade®) or Etanercept (Enbrel®) within the past 3 months or 5 half lives (whichever is shorter).~5. History of renal insufficiency~6. History of hepatic dysfunction~7. History of adrenal Insufficiency~8. History of vascular or metabolic disease including existing or previous arterial thromboembolic diseases (myocardial infarction, stroke), existing or previous venous thromboembolic diseases (deep vein thrombosis, pulmonary embolism), and any condition which could increase the risk to suffer any of the above mentioned disorders~9. History of hypertension~10. History of Diabetes mellitus with vascular involvement~11. Migraine headaches with focal neurological symptoms~12. Major surgery with prolonged immobilization~13. Known or suspected carcinoma of the breast~14. History of Carcinoma of the endometrium or other known or suspected estrogen-dependent neoplasia~15. Undiagnosed abnormal genital bleeding~16. Cholestatic jaundice of pregnancy or jaundice with prior pill use~17. History of Liver tumor (benign or malignant) or active liver disease~18. Smokers~19. Regular intake of medications that may increase potassium levels such as NSAIDS, potassium sparing diuretics, potassium supplementation, ACE inhibitors, Angiotensin-II receptor antagonists, heparin and aldosterone antagonists.~20. Hypersensitivity to any component of the study drug~21. Clinically significant abnormal findings or conditions (other than acne), which might, in the opinion of the Principal Investigator, interfere with study evaluations or pose a risk to subject safety during the study.~22. Subjects who are known to be pregnant or planning a pregnancy.

- Gender: FEMALE
- Minimum Age: 14 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): drospirenone and ethinyl estradiol
- B (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Rheumatoid Arthritis:Tolerance Induction by Mixed Chimerism

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Participant Inclusion Criteria:~* Age \> 18 and \< 60 years at time of pre-transplant evaluation.~* An established clinical diagnosis of rheumatoid arthritis by American College of Rheumatology criteria.~* Patients must have failed an autologous hematopoietic transplant or have failed to respond to either methotrexate or leflunomide in combination with a TNF inhibitor. Failure is defined as an inability to tolerate treatment with at least 6 swollen joints and 20 involved joints or inability to answer at least 70% of HAQ questions with no difficulty despite 2 or more months of treatment.~  * Ability to give informed consent.~ * Patient must have a HLA matched sibling donor at the A, B, C, and DR loci to proceed or HLA matched cord blood donor.~ * If donor is HLA matched cord blood, cord blood stem cells will be obtained from the NMDP (1-800-548-1375) and one or two units of HLA matched cord blood will be infused on day zero.~Participant Exclusion Criteria~* History of coronary artery disease, or documented congestive heart failure.~* HIV positive.~* Uncontrolled diabetes mellitus, or any other illness that in the opinion of the investigators would jeopardize the ability of the patient to tolerate aggressive chemoradiotherapy.~* Prior history of malignancy except localized basal cell or squamous skin cancer. Other malignancies for which the patient is judged to be cured by local surgical therapy, such as head and neck cancer, or stage I breast cancer will be considered on an individual basis.~* Positive pregnancy test, inability or unwillingness to pursue effective means of birth control, failure to willingly accept or comprehend irreversible sterility as a side effect of therapy.~* Psychiatric illness or mental deficiency making compliance with treatment or informed consent impossible.~* FEV1/FVC \< 70% of predicted, DLCO \< 40% of predicted.~* Resting LVEF \< 45 %.~* Bilirubin \> 2.0 mg/dl (unless due to Gilberts), transferase (AST) \> 2.5 x upper limit of normal.~* Serum creatinine \> 2.0 mg/dl.~Donor Exclusion Criteria~* Age \< 18 years.~* Positive for HIV-1, HIV-2, HTLV-I, HTLV-II.~* Active hepatitis B or C.~* History of a malignancy except for a localized cancer such as skin cancer that is deemed cured.~* History of myocardial infarction or congestive heart failure.~* Inability to give informed consent.~* Current pregnancy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Hematopoietic Stem Cell Transplantation (Type: EXPERIMENTAL): Allogeneic Hematopoietic Stem Cell Transplantation will be performed on eligible patients diagnosed with RA

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Prospective, Multicenter, Randomized Control Study To Determine Clinical Effectiveness, Patient Wellness and Cost of Pain Related Care of In-Elastic Lumbar Sacral Orthoses Versus Standard Medical Treatment in Patients Presenting With Acute Low Back Pain In Primary Care Centers (The ARREST Study)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
* Inclusion Criteria:~  o Moderate to complete disability (baseline ODI score of 21 to 80 percent)~* Exclusion Criteria:~  * Pregnant patients~ * Patients considering pregnancy~ * Patients in any other investigational device or drug study~ * Patients unwilling to return for follow up~ * Patients unwilling to provide access to medical claims associated with pain management.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention (Aspen Horizon 627 LSO) (Type: EXPERIMENTAL): Patients receive a lumbar brace, Aspen Horizon 627 LSO, in addition to normal medical management
- Medical Management (Type: NO_INTERVENTION): Normal medical management

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: EUS Evaluation of Perianal and Peri-rectal Fistulizing Crohn's Disease With CERTOLIZUMAB Treatment

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Conventional therapy here indicates non-biologic therapy. Study subjects would have failed conventional and standard regimens of treatment such as immunomodulators (azathioprine, 6-mercaptopurine, methotrexate) or mesalamines or corticosteroids. Certolizumab is actually an approved regimen of treatment for Crohn's disease as patients with perianal fistulas fall under those with moderately to severely active disease. It is not an off-label indication, therefore would not require an IND. The study goal is to look at EUS as a tool to determine how fistula healing occurs with the use of certolizumab which is one of the biologic therapies used to treat fistulizing Crohn's disease. Crohn's disease patients with peri-anal or peri-rectal fistulizing disease. Moderate to severe Crohn's disease patients between the ages of 18 and 70 years with active peri-anal or peri-rectal fistula.~Exclusion Criteria:~* Pre-existing fistula improving on current medical therapy. Contraindication to certolizumab use. Prior use of anti-TNF-alpha.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Certolizumab (Type: None): Subjects will take the study drug certolizumab for 8 weeks. They will undergo a endoscopy before study drug and then again after study is complete. The study doctor will be looking for complete closure of the peri-anal fistula identified at visit 1 after the use of certolizumab based on and endoscopic ultrasound (EUS).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues